Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma

Authors: Yu Liang, Andrew W Bollen, Ken D Aldape, Nalin Gupta

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

We previously identified brain type fatty acid-binding protein (FABP7) as a prognostic marker for patients with glioblastoma (GBM). Increased expression of FABP7 is associated with reduced survival. To investigate possible molecular mechanisms underlying this association, we compared the expression and subcellular localization of FABP7 in non-tumor brain tissues with different types of glioma, and examined the expression of FABP7 and epidermal growth factor receptor (EGFR) in GBM tumors.

Methods

Expression of FABP7 in non-tumor brain and glioma specimens was examined using immunohistochemistry, and its correlation to the clinical behavior of the tumors was analyzed. We also analyzed the association between FABP7 and EGFR expression in different sets of GBM specimens using published DNA microarray datasets and semi-quantitative immunohistochemistry. In vitro migration was examined using SF763 glioma cell line.

Results

FABP7 was present in a unique population of glia in normal human brain, and its expression was increased in a subset of reactive astrocytes. FABP7 immunoreactivity in grade I pilocytic astrocytoma was predominantly cytoplasmic, whereas nuclear FABP7 was detected in other types of infiltrative glioma. Nuclear, not cytoplasmic, FABP7 immunoreactivity was associated with EGFR overexpression in GBM (N = 61, p = 0.008). Expression of the FABP7 gene in GBM also correlated with the abundance of EGFR mRNA in our previous microarray analyses (N = 34, p = 0.016) and an independent public microarray dataset (N = 28, p = 0.03). Compared to those negative for both markers, nuclear FABP7-positive/EGFR-positive and nuclear FABP7-positive/EGFR-negative GBM tumors demonstrated shortest survival, whereas those only positive for EGFR had intermediate survival. EGFR activation increased nuclear FABP7 immunoreactivity in a glioma cell line in vitro, and inhibition of FABP7 expression suppressed EGF-induced glioma-cell migration. Our data suggested that in EGFR-positive GBM the presence of nuclear FABP7 immunoreactivity increases the risk of poor prognosis

Conclusion

In this study, we identified a possible mechanism as the basis of the association between nuclear FABP7 and poor prognosis of GBM. FABP7 expression can be found in all grades of astrocytoma, but neoplastic cells with nuclear FABP7 were only seen in infiltrative types of tumors. Nuclear FABP7 may be induced by EGFR activation to promote migration of GBM tumor cells. Positive nuclear FABP7 and EGFR overexpression correlated with short survival in EGFR-positive GBM patients. Therefore, nuclear FABP7 immunoreactivity could be used to monitor the progression of EGFR-overexpressed GBM.
Appendix
Available only for authorised users
Literature
1.
Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001, 19 (2): 509-518.
2.
Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997, 75 (9): 1269-1278.CrossRefPubMedPubMedCentral
3.
Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G: Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res. 1998, 4 (10): 2383-2390.PubMed
4.
Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol. 1997, 35 (1): 13-28. 10.1023/A:1005841520514.CrossRefPubMed
5.
Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumcke I, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg. 1996, 85 (4): 634-641.CrossRefPubMed
6.
Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998, 8 (4): 655-667.CrossRefPubMed
7.
Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001, 61 (3): 1122-1128.PubMed
8.
Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN: Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004, 10 (1 Pt 1): 228-233. 10.1158/1078-0432.CCR-0841-3.CrossRefPubMed
9.
Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005, 102 (16): 5814-5819. 10.1073/pnas.0402870102.CrossRefPubMedPubMedCentral
10.
Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA: SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res. 2003, 31 (1): 219-223. 10.1093/nar/gkg014.CrossRefPubMedPubMedCentral
11.
Feng L, Hatten ME, Heintz N: Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. Neuron. 1994, 12 (4): 895-908. 10.1016/0896-6273(94)90341-7.CrossRefPubMed
12.
Godbout R, Bisgrove DA, Shkolny D, Day RS: Correlation of B-FABP and GFAP expression in malignant glioma. Oncogene. 1998, 16 (15): 1955-1962. 10.1038/sj.onc.1201740.CrossRefPubMed
13.
Miller SJ, Li H, Rizvi TA, Huang Y, Johansson G, Bowersock J, Sidani A, Vitullo J, Vogel K, Parysek LM, DeClue JE, Ratner N: Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Mol Cell Biol. 2003, 23 (6): 2213-2224. 10.1128/MCB.23.6.2213-2224.2003.CrossRefPubMedPubMedCentral
14.
Owada Y, Yoshimoto T, Kondo H: Increased expression of the mRNA for brain- and skin-type but not heart-type fatty acid binding proteins following kainic acid systemic administration in the hippocampal glia of adult rats. Brain Res Mol Brain Res. 1996, 42 (1): 156-160. 10.1016/S0169-328X(96)00182-9.CrossRefPubMed
15.
Xu LZ, Sanchez R, Sali A, Heintz N: Ligand specificity of brain lipid-binding protein. JBiol Chem. 1996, 271 (40): 24711-24719.CrossRef
16.
Feng L, Heintz N: Differentiating neurons activate transcription of the brain lipid-binding protein gene in radial glia through a novel regulatory element. Development. 1995, 121 (6): 1719-1730.PubMed
17.
Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara T: Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). Biochim Biophys Acta. 1997, 1354 (1): 24-28.CrossRefPubMed
18.
Khan SH, Sorof S: Liver fatty acid-binding protein: specific mediator of the mitogenesis induced by two classes of carcinogenic peroxisome proliferators. Proc Natl Acad Sci U S A. 1994, 91 (3): 848-852.CrossRefPubMedPubMedCentral
19.
Shi YE, Ni J, Xiao G, Liu YE, Fuchs A, Yu G, Su J, Cosgrove JM, Xing L, Zhang M, Li J, Aggarwal BB, Meager A, Gentz R: Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res. 1997, 57 (15): 3084-3091.PubMed
20.
Wang M, Liu YE, Ni J, Aygun B, Goldberg ID, Shi YE: Induction of mammary differentiation by mammary-derived growth inhibitor-related gene that interacts with an omega-3 fatty acid on growth inhibition of breast cancer cells. Cancer Res. 2000, 60 (22): 6482-6487.PubMed
21.
Glatz JF, Luiken JJ, van Bilsen M, van der Vusse GJ: Cellular lipid binding proteins as facilitators and regulators of lipid metabolism. Mol Cell Biochem. 2002, 239 (1–2): 3-7. 10.1023/A:1020529918782.CrossRefPubMed
22.
Wolfrum C, Borrmann CM, Borchers T, Spener F: Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha – and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A. 2001, 98 (5): 2323-2328. 10.1073/pnas.051619898.CrossRefPubMedPubMedCentral
23.
Huang H, Starodub O, McIntosh A, Kier AB, Schroeder F: Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells. J Biol Chem. 2002, 277 (32): 29139-29151. 10.1074/jbc.M202923200.CrossRefPubMed
24.
Huang H, Starodub O, McIntosh A, Atshaves BP, Woldegiorgis G, Kier AB, Schroeder F: Liver fatty acid-binding protein colocalizes with peroxisome proliferator activated receptor alpha and enhances ligand distribution to nuclei of living cells. Biochemistry. 2004, 43 (9): 2484-2500. 10.1021/bi0352318.CrossRefPubMed
25.
Abdelwahab SA, Owada Y, Kitanaka N, Iwasa H, Sakagami H, Kondo H: Localization of brain-type fatty acid-binding protein in Kupffer cells of mice and its transient decrease in response to lipopolysaccharide. Histochem Cell Biol. 2003, 119 (6): 469-475. 10.1007/s00418-003-0538-z.CrossRefPubMed
26.
Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO: Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001, 61 (13): 4956-4960.PubMed
27.
Kurtz A, Zimmer A, Schnutgen F, Bruning G, Spener F, Muller T: The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development. 1994, 120 (9): 2637-2649.PubMed
28.
Gutmann DH, Hedrick NM, Li J, Nagarajan R, Perry A, Watson MA: Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. Cancer Res. 2002, 62 (7): 2085-2091.PubMed
29.
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005, 65 (5): 1678-1686. 10.1158/0008-5472.CAN-04-2921.CrossRefPubMed
30.
Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003, 63 (7): 1602-1607.PubMed
31.
Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD: Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res. 1990, 50 (18): 6039-6044.PubMed
32.
Das R, Hammamieh R, Neill R, Melhem M, Jett M: Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin Cancer Res. 2001, 7 (6): 1706-1715.PubMed
33.
Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63 (20): 6962-6970.PubMed
34.
Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, Staugaitis SM: Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A. 1999, 96 (18): 10361-10366. 10.1073/pnas.96.18.10361.CrossRefPubMedPubMedCentral
35.
Nishiyama A, Chang A, Trapp BD: NG2+ glial cells: a novel glial cell population in the adult brain. J Neuropathol Exp Neurol. 1999, 58 (11): 1113-1124.CrossRefPubMed
36.
Liang Y, Bollen AW, Nicholas K, Gupta N: Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas. BMC Clin Pathol. 2005, 5 (1): 6-10.1186/1472-6890-5-6.CrossRefPubMedPubMedCentral
37.
Wunderlich MT, Hanhoff T, Goertler M, Spener F, Glatz JF, Wallesch CW, Pelsers MM: Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol. 2005, 252 (6): 718-724. 10.1007/s00415-005-0725-z.CrossRefPubMed
38.
de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ, van Muijen GN: Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer. 2005, 92 (12): 2249-2261. 10.1038/sj.bjc.6602612.CrossRefPubMedPubMedCentral
Metadata
Title
Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma
Authors
Yu Liang
Andrew W Bollen
Ken D Aldape
Nalin Gupta
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-97

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Case report

Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature

Research article

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families

Research article

The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma

Research article

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Research article

Effects of estradiol and medroxyprogesterone acetate on morphology, proliferation and apoptosis of human breast tissue in organ cultures

Erratum

Erratum to: a method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits